Patients with valvular heart disease (VHD) are at increased risk for thrombo-emboligenic events and often require antithrombotic therapy. This needs to be clearly weighted against the bleeding risk as this is often also increased. This chapter will provide an overview of current evidence available in patients with VHD. We will discuss general indications of antithrombotic therapy, its duration, dose, bridging during procedures and treatment options during pregnancy.

Originele taal-2English
TitelHeart Valve Disease
SubtitelState of the Art
UitgeverijSpringer International Publishing AG
Aantal pagina's12
ISBN van elektronische versie9783030231040
ISBN van geprinte versie9783030231033
StatusPublished - 1 jan 2019


Duik in de onderzoeksthema's van 'Antithrombotic therapy in valvular heart disease'. Samen vormen ze een unieke vingerafdruk.

Citeer dit